Richland WA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) Vivos Inc is pleased to report that its attendance and presentation at the annual meeting of the Veterinary Cancer Society in Louisville, Kentucky was very well received. A significant number of the attendees stopped by the company’s exhibit booth and learned about IsoPet® and the successful treatment of sarcomas in cats and dogs.
On Saturday morning, Dr. Korenko had the honor of introducing the keynote speaker, and later that morning offered his own presentation on the efficacy of IsoPet® before several hundred veterinary professionals. It was the first time that Vivos has presented to leaders in the Veterinary cancer specialty since receiving FDA device classification clearing the way for commercial use of IsoPet® for veterinary applications. Dr. Korenko also announced at this conference that Vivos is now accepting expressions of interest from veterinary oncologists and radiologists interested in establishing regional treatment centers.
The presentation was streamed over the internet and over 300 people viewed it live.
The conference was also attended by the Chair of our Veterinarian Medicine Advisory Board, the renowned oncologist and author, Dr. Alice Villalobos, who continued her enthusiastic support of treating cancerous tumors in animals using IsoPet®.
Vivos Inc received strong interest from several clinics to become regional therapy centers for IsoPet. We will begin the next stage of the selection process by comparing the candidates against our target regions and then engage in a series of detailed discussions. We are targeting to sign Memorandums of Understanding with five clinics and to have them operational by mid- 2019.
We have already learned valuable information from our current effort to qualify our local pilot clinic in Kennewick WA, which we will translate to these new clinics.
Dr. Mike Korenko, Vivos CEO stated “I am pleased with the strong interest in IsoPet® from the practicing veterinary oncology community and are confident that our strategic plan is on course. There are some additional exciting initiatives that we plan on pursuing in the near future. At the conference, we initiated discussions with a company that is interested in working with us on a combination therapy that would be applicable for patients with more advanced disease. We would use IsoPet® to treat the primary tumors and would follow with their immunotherapy treatment to target cells that have metastasized. This combined therapy approach would broaden the application of IsoPet® for use on these very advanced cases and would be an option for animals that were considered terminal.”
About Vivos Inc. (RDGL)
Vivos, Inc. is a pharmaceutical company researching and developing minimally invasive treatments to combat cancer in humans and animals. It has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.
The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.
The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.
The Company is also engaging the FDA for clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.